CN110248668B - 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 - Google Patents

用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 Download PDF

Info

Publication number
CN110248668B
CN110248668B CN201780085237.6A CN201780085237A CN110248668B CN 110248668 B CN110248668 B CN 110248668B CN 201780085237 A CN201780085237 A CN 201780085237A CN 110248668 B CN110248668 B CN 110248668B
Authority
CN
China
Prior art keywords
antibody
seq
ser
cells
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780085237.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110248668A (zh
Inventor
T·F·特德
Y·藤泽
J·莱肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN110248668A publication Critical patent/CN110248668A/zh
Application granted granted Critical
Publication of CN110248668B publication Critical patent/CN110248668B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780085237.6A 2016-12-15 2017-12-15 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 Expired - Fee Related CN110248668B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434833P 2016-12-15 2016-12-15
US62/434,833 2016-12-15
PCT/US2017/066815 WO2018112407A1 (en) 2016-12-15 2017-12-15 Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
CN110248668A CN110248668A (zh) 2019-09-17
CN110248668B true CN110248668B (zh) 2023-05-30

Family

ID=62559412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085237.6A Expired - Fee Related CN110248668B (zh) 2016-12-15 2017-12-15 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用

Country Status (5)

Country Link
US (1) US11230598B2 (cg-RX-API-DMAC7.html)
EP (1) EP3554515A4 (cg-RX-API-DMAC7.html)
JP (2) JP7252627B2 (cg-RX-API-DMAC7.html)
CN (1) CN110248668B (cg-RX-API-DMAC7.html)
WO (1) WO2018112407A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
CN110248668B (zh) * 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
EP3816161A4 (en) 2018-06-25 2022-03-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTALLINE FACIES OF A QUINOLINE DERIVATIVE AND METHOD FOR PREPARING A CRYSTALLINE POWDER THEREOF
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
WO2021133476A1 (en) * 2019-12-24 2021-07-01 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
EP4204008A1 (en) * 2020-08-26 2023-07-05 Citius Pharmaceuticals, Inc. Combination for use in methods of treating cancer
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
JP2024502758A (ja) * 2021-01-13 2024-01-23 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３結合タンパク質及びその使用
CN117083301A (zh) * 2021-02-03 2023-11-17 先声再明医药有限公司 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164731A2 (en) * 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5298614A (en) 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO1997034632A1 (en) 1996-03-20 1997-09-25 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO2000047601A1 (en) 1999-02-15 2000-08-17 Nippon Shinyaku Co. Ltd. Shortened-chain polynucleotides and process for the preparation thereof
ATE440618T1 (de) 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
EP1539234A4 (en) 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004094671A2 (en) 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
US20060120997A1 (en) 2004-10-29 2006-06-08 Biomune, Inc. Cancer therapeutic compositions
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
AU2007223903B2 (en) 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TWI423814B (zh) 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
PL2594586T3 (pl) * 2006-09-01 2015-02-27 Zymogenetics Inc Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2084527A4 (en) 2006-11-02 2011-07-27 Seattle Genetics Inc METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
KR20100063048A (ko) 2007-07-31 2010-06-10 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
WO2009105150A2 (en) 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
KR20140102764A (ko) 2009-05-13 2014-08-22 겐자임 코포레이션 항-인간 ｃｄ52 면역글루불린
SI2400298T1 (sl) 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US10131875B2 (en) * 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
WO2012088272A1 (en) 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN110248668B (zh) * 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164731A2 (en) * 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
肿瘤免疫检查点抑制剂临床治疗的研究进展;许标波等;《中国临床药理学与治疗学》;20160221;218-224 *
调节性B细胞在慢性炎症疾病及自身免疫疾病的作用机制;孙雪等;《辽宁医学杂志》;20111231;第25卷(第4期);200-202 *
调节性B细胞的研究进展;张影等;《临床肺科杂志》;20121031;第17卷(第10期);1868-1869 *

Also Published As

Publication number Publication date
US11230598B2 (en) 2022-01-25
EP3554515A1 (en) 2019-10-23
CN110248668A (zh) 2019-09-17
JP2020502147A (ja) 2020-01-23
EP3554515A4 (en) 2020-08-26
JP2023026426A (ja) 2023-02-24
US20190367607A1 (en) 2019-12-05
WO2018112407A1 (en) 2018-06-21
JP7252627B2 (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
CN110248668B (zh) 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
US10688180B2 (en) Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
RU2759970C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
US20230111786A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
US20250171538A1 (en) Tim-3 antagonists for the treatment and diagnosis of cancers
JP6970099B2 (ja) ガンの処置のための方法及び医薬組成物
US20170015758A1 (en) Compositions And Methods For Modulating And Redirecting Immune Responses
JP2019503361A (ja) がんを治療するための抗ｐｄ−１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
JP7170331B2 (ja) 固形及び血液癌の治療のための併用療法
JP2021178835A (ja) 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用
JP2021534088A (ja) 免疫療法とｍｄｍ２阻害剤の併用
JP2020525517A (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
KR20200074214A (ko) 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
US20250101097A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
RU2773655C2 (ru) Комбинация, содержащая перенаправляющие т-клетки многофункциональные антитела и модуляторы контрольных точек, и ее применения
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion
HK1253022B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
BR112016010557B1 (pt) Uso de um anticorpo monoclonal para ceacam1 humana, ou um fragmento de ligação ao antígeno do mesmo e um anticorpo monoclonal para pd-1 humana ou um fragmento de ligação ao antígeno do mesmo e kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230530